Search

Glycolic acid

Probenecid

It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. … Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.

Tebentafusp

[L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675] … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism

Dichromate

Phenyl trimethicone

Tasimelteon

Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010. … Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness.

1,2-dichlorobenzene

1,2-Dichlorobenzene, also named ortho-dichlorobenzene, is an organic compound. It is a non-polar colorless liquid that is miscible in most organic solvents. … This derivative of benzene differs from the parent compound by the presence of two adjacent chlorine atoms. 1,2-dichlorobenzene is used as a precursor for agrochemicals, as a solvent for fullerenes, as

Colfosceril palmitate

Colfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome. … [A31510] It was part of the first generation of commercially available artificial surfactants.[T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990.

Simeprevir

Broad use of simeprevir occurred when it was used in combination with a newer drug, [DB08934]. … It is shown to display synergistic effects with interferon-α and HCV NS5B inhibitor, and additive effects with ribavirin in HCV replicon cells [A19629].

Marnetegragene autotemcel

Severe leukocyte adhesion deficiency-I (LAD-I) is a genetic disorder leading to frequent life-threatening infections and high fatality risks among affected pediatric patients. … [L56115, L56116] Marnetegragene autotemcel is indicated for pediatric patients with severe LAD-I lacking an available HLA-matched sibling donor.[L56115]